de Haan G, Ausema A, Wilkens M, Molineux G, Dontje B
Department of Cell Biology, University of Groningen, Groningen, the Netherlands.
Br J Haematol. 2000 Sep;110(3):638-46. doi: 10.1046/j.1365-2141.2000.02252.x.
We have compared the efficacy of a single injection of SD/01, a newly engineered, pegylated form of recombinant human granulocyte colony stimulating factor (rhG-CSF), with a single injection of glycosylated rhG-CSF (Filgrastim). SD/01 was administered to regular and recombinant inbred strains of mice (AKR, C57L/J, DBA/2, C57BL/6, AKXL) known to have widely distinct marrow-cell pool sizes and proliferation kinetics. A single injection of G-CSF was unable to mobilize granulocyte-macrophage colony-forming units (CFU-GM). In sharp contrast, a single dose of SD/01 resulted in massive mobilization of progenitors and stem cells. Although all mice strains showed qualitatively similar mobilization responses, large interstrain differences remained. C57L and C57BL/6 mice mobilized relatively poorly, whereas AKR and DBA/2 mice showed threefold to tenfold superior responses. In order to explain these different phenotypes, we studied the effects of SD/01 in nine AKXL recombinant inbred strains, derived from well-responding AKR and poorly responding C57L parental strains. The best predictor for SD/01 responsiveness in these strains was marrow cellularity prior to mobilization. Comparison of the AKXL strain distribution pattern for marrow cellularity with loci previously mapped in these strains showed complete concordance with Aat, a serine protease inhibitor mapping to chromosome 12.
我们比较了单次注射SD/01(一种新设计的聚乙二醇化重组人粒细胞集落刺激因子(rhG-CSF))与单次注射糖基化rhG-CSF(非格司亭)的疗效。SD/01被给予已知具有广泛不同骨髓细胞池大小和增殖动力学的常规和重组近交系小鼠(AKR、C57L/J、DBA/2、C57BL/6、AKXL)。单次注射G-CSF无法动员粒细胞-巨噬细胞集落形成单位(CFU-GM)。与之形成鲜明对比的是,单次剂量的SD/01导致祖细胞和干细胞大量动员。尽管所有小鼠品系在定性上表现出相似的动员反应,但品系间仍存在很大差异。C57L和C57BL/6小鼠的动员效果相对较差,而AKR和DBA/2小鼠的反应则高出三到十倍。为了解释这些不同的表型,我们研究了SD/01对来自反应良好的AKR和反应较差的C57L亲本品系的九个AKXL重组近交系的影响。这些品系中SD/01反应性的最佳预测指标是动员前的骨髓细胞密度。将骨髓细胞密度的AKXL品系分布模式与先前在这些品系中定位的基因座进行比较,结果显示与位于12号染色体上的丝氨酸蛋白酶抑制剂Aat完全一致。